龍津藥業(002750.SZ):前三季淨利預增5.66%至49.18%
格隆匯10月14日丨龍津藥業(002750.SZ)發佈2020年前三季度業績預告,歸屬於上市公司股東的淨利潤190.82萬元至269.41萬元,同比增長5.66%至49.18%。
2020年第三季度歸屬於上市公司股東的淨利潤351.47萬元至430.06萬元,同比增長654.55%至823.28%。
本報告期,受新冠病毒疫情,以及醫保支付、醫院處方限制政策持續執行的影響,公司產品銷量、營業收入較上年同期下降,但降幅同比收窄,最近兩個季度銷售收入環比增加;受疫情和公司經營現狀影響,公司銷售費用降低;同時,因公司管理層主動降薪、母公司管理費用下降等因素,導致歸屬於上市公司股東的淨利潤較去年同期增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.